CD8A and neoplasm: In addition to the aforementioned CD8+ T cells, other smaller subsets, such as tumor-promoting T regulatory lymphocytes and T helper 2 (Th2) lymphocytes, as well as tumor-inhibiting T helper 1 (Th1) lymphocytes, have a clearer impact on anticancer immunity [11,12].